RU2016122168A - Антисмысловые конъюгаты, направленные на аполипопротеин b - Google Patents
Антисмысловые конъюгаты, направленные на аполипопротеин b Download PDFInfo
- Publication number
- RU2016122168A RU2016122168A RU2016122168A RU2016122168A RU2016122168A RU 2016122168 A RU2016122168 A RU 2016122168A RU 2016122168 A RU2016122168 A RU 2016122168A RU 2016122168 A RU2016122168 A RU 2016122168A RU 2016122168 A RU2016122168 A RU 2016122168A
- Authority
- RU
- Russia
- Prior art keywords
- antisense oligonucleotide
- conjugate
- linker
- oligomer
- conjugated fragment
- Prior art date
Links
- 101710095342 Apolipoprotein B Proteins 0.000 title 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 239000000074 antisense oligonucleotide Substances 0.000 claims 15
- 238000012230 antisense oligonucleotides Methods 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 8
- 102000018616 Apolipoproteins B Human genes 0.000 claims 5
- 108010027006 Apolipoproteins B Proteins 0.000 claims 5
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Конъюгат антисмыслового олигонуклеотида, содержащий олигомер с олигонуклеотидным мотивом SEQ ID NO 2, присоединенный к конъюгированному фрагменту (сегменту С), где конъюгированный фрагмент содержит одну или более групп N-ацетилгалактозамина.
2. Конъюгат антисмыслового олигонуклеотида по п. 1, где олигомер содержит по меньшей мере 2 аналога нуклеотида, повышающих аффинность, выбранных из группы, состоящей из звеньев закрытой нуклеиновой кислоты (LNA); звеньев 2'-O-алкил-РНК, звеньев 2'-ОМе-РНК, звеньев 2'-амино-ДНК и звеньев 2'-фтор-ДНК.
3. Конъюгат антисмыслового олигонуклеотида по п. 1, где олигомер соответствует SEQ ID NO 27: 5' GsTstsgsascsascstsgsTsC 3', где заглавные буквы означают бета-D-окси LNA, строчные буквы означают ДНК нуклеозиды, цитозины LNA представляют собой 5-метилцитозин, и все межнуклеозидные связи являются фосфоротиоатными, обозначенными символом s.
4. Конъюгат антисмыслового олигонуклеотида по п. 1, где олигомер способен снижать экспрессию АроВ в клетках, экспрессирующих АроВ.
5. Конъюгат антисмыслового олигонуклеотида по п. 1, где указанный конъюгированный фрагмент присоединен к указанному олигомеру посредством расщепляемого линкера (В).
6. Конъюгат антисмыслового олигонуклеотида по п. 5, где расщепляемый линкер содержит расщепляемый лизиновый линкер.
7. Конъюгат антисмыслового олигонуклеотида по п. 1, где конъюгированный фрагмент содержит от 1 до 3 групп N-ацетилгалактозамина.
8. Конъюгат антисмыслового олигонуклеотида по п. 1, где конъюгат олигонуклеотида содержит линкер Y, ковалентно связывающий конъюгированный фрагмент с олигомером.
9. Конъюгат антисмыслового олигонуклеотида по п. 8, где область линкера Y содержит жирную кислоту такую как С6 линкер.
10. Конъюгат антисмыслового олигонуклеотида по п. 1, где конъюгированный фрагмент содержит ПЭГ (от англ. polyethyleneglycol - полиэтиленгликоль) спейсер между группой (группами) N-ацетилгалактозамина и линкером (В и/или Y) или олигомером.
11. Конъюгат антисмыслового олигонуклеотида по п. 1, где конъюгированный фрагмент содержит три группы N-ацетилгалактозамина, каждая из которых независимо связана посредством ПЭГ спейсера с расщепляемым ди-лизиновым линкером.
12. Конъюгат антисмыслового олигонуклеотида по п. 1, где конъюгат содержит конъюгированный фрагмент, выбранный из группы, состоящей из Conj1, Conj2, Conj3, Conj4, Conj1a, Conj2a, Conj3a и Conj4a.
13. Конъюгат антисмыслового олигонуклеотида по п. 1, который состоит из SEQ ID NO 29 или SEQ ID NO 31.
14. Фармацевтическая композиция, содержащая конъюгат антисмыслового олигонуклеотида по любому из пп. 1-13 и фармацевтически приемлемый разбавитель, носитель, соль или адъювант.
15. Конъюгат антисмыслового олигонуклеотида или фармацевтическая композиция по любому из пп. 1-14 для применения в качестве лекарственного средства.
16. Способ ингибирования in vivo или in vitro АроВ в клетке, экспрессирующей АроВ, указанный способ включает введение конъюгата олигонуклеотида или фармацевтической композиции по любому из пп. 1-14 в указанную клетку для ингибирования АроВ в указанной клетке.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/073859 WO2014076196A1 (en) | 2012-11-15 | 2013-11-14 | Anti apob antisense conjugate compounds |
| EPPCT/EP2013/073859 | 2013-11-14 | ||
| EPPCT/EP2013/073858 | 2013-11-14 | ||
| EP13192930 | 2013-11-14 | ||
| PCT/EP2013/073858 WO2014076195A1 (en) | 2012-11-15 | 2013-11-14 | Oligonucleotide conjugates |
| EP13192930.9 | 2013-11-14 | ||
| EP14153266 | 2014-01-30 | ||
| EP14153266.3 | 2014-01-30 | ||
| EP14167879.7 | 2014-05-12 | ||
| EP14167879 | 2014-05-12 | ||
| PCT/EP2014/074554 WO2015071388A1 (en) | 2013-11-14 | 2014-11-14 | Apob antisense conjugate compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016122168A true RU2016122168A (ru) | 2017-12-19 |
Family
ID=53056817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016122168A RU2016122168A (ru) | 2013-11-14 | 2014-11-14 | Антисмысловые конъюгаты, направленные на аполипопротеин b |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160289677A1 (ru) |
| EP (1) | EP3068885A1 (ru) |
| JP (1) | JP2017501684A (ru) |
| KR (1) | KR20160083876A (ru) |
| CN (1) | CN105722980A (ru) |
| CA (1) | CA2928349A1 (ru) |
| HK (1) | HK1220724A1 (ru) |
| MX (1) | MX2016005855A (ru) |
| RU (1) | RU2016122168A (ru) |
| WO (1) | WO2015071388A1 (ru) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003281969B2 (en) | 2002-11-18 | 2011-01-27 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| EP2370451B1 (en) | 2008-12-02 | 2016-11-16 | Wave Life Sciences Japan, Inc. | Method for the synthesis of phosphorus atom modified nucleic acids |
| KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| CN117126846A (zh) | 2012-11-15 | 2023-11-28 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸缀合物 |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP4137572A1 (en) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
| KR20200102553A (ko) | 2014-05-01 | 2020-08-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법 |
| KR102579520B1 (ko) | 2015-08-06 | 2023-09-15 | 에프. 호프만-라 로슈 아게 | Galnac 산 유도체의 제조 방법 |
| US20210052631A1 (en) * | 2015-09-25 | 2021-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| KR20180056766A (ko) * | 2015-10-09 | 2018-05-29 | 웨이브 라이프 사이언시스 리미티드 | 뉴클레오티드 조성물 및 이의 방법 |
| CN108738321B (zh) | 2015-11-16 | 2021-06-11 | 豪夫迈·罗氏有限公司 | GalNAc簇亚磷酰胺 |
| WO2017178656A1 (en) | 2016-04-14 | 2017-10-19 | Roche Innovation Center Copenhagen A/S | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE |
| US20220354888A1 (en) | 2016-08-03 | 2022-11-10 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| US11963974B2 (en) | 2017-03-10 | 2024-04-23 | National Center For Child Health And Development | Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
| CN115976028B (zh) * | 2018-03-09 | 2025-03-25 | 第一三共株式会社 | 糖原病Ia型治疗药 |
| WO2021261998A1 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
| CN116437965A (zh) * | 2020-09-10 | 2023-07-14 | 萨普雷米科技有限公司 | 皂苷、寡核苷酸和galnac的缀合物 |
| WO2022055352A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| EP4210761B8 (en) * | 2020-09-10 | 2025-09-24 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| WO2022055351A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| WO2022164316A1 (en) * | 2021-01-26 | 2022-08-04 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| TW202246500A (zh) * | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| AU2022245292A1 (en) | 2021-03-26 | 2023-10-12 | Neumirna Therapeutics Aps | Microrna-134 inhibitors |
| EP4313074A1 (en) | 2021-03-26 | 2024-02-07 | Neumirna Therapeutics ApS | Microrna-27b inhibitors |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| WO2022254021A1 (en) | 2021-06-04 | 2022-12-08 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
| EP4591938A3 (en) * | 2021-06-18 | 2025-11-05 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| JP2024531342A (ja) | 2021-08-19 | 2024-08-29 | ニューミルナ セラピューティクス エーピーエス | アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド |
| WO2023038517A1 (en) * | 2021-09-09 | 2023-03-16 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| CN115487308B (zh) * | 2022-09-29 | 2024-09-27 | 北京大学 | 反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用 |
| EP4512899A1 (en) | 2023-08-23 | 2025-02-26 | Lipigon Pharmaceuticals AB | Angptl4 aso compositions for treatment of atherosclerosis in humans |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507499A (ja) * | 2005-09-15 | 2009-02-26 | サンタリス ファーマ アー／エス | Ａｐｏ−ｂ１００発現の抑制のためのｒｎａアンタゴニスト化合物 |
| JP5635412B2 (ja) * | 2007-12-04 | 2014-12-03 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的化脂質 |
| EP2384197B1 (en) * | 2008-12-31 | 2016-04-06 | Roche Innovation Center Copenhagen A/S | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
| CA2764822A1 (en) * | 2009-06-12 | 2010-12-16 | Santaris Pharma A/S | New potent anti apob antisense compounds |
| CN102869774B (zh) * | 2010-02-24 | 2018-02-09 | 箭头研究公司 | 用于靶向递送siRNA的组合物 |
| MX346144B (es) * | 2010-12-17 | 2017-03-09 | Arrowhead Res Corp * | Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi. |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| DK2991656T3 (da) * | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
-
2014
- 2014-11-14 US US15/036,218 patent/US20160289677A1/en not_active Abandoned
- 2014-11-14 EP EP14799402.4A patent/EP3068885A1/en not_active Withdrawn
- 2014-11-14 JP JP2016530901A patent/JP2017501684A/ja active Pending
- 2014-11-14 RU RU2016122168A patent/RU2016122168A/ru unknown
- 2014-11-14 KR KR1020167012465A patent/KR20160083876A/ko not_active Withdrawn
- 2014-11-14 CN CN201480061955.6A patent/CN105722980A/zh active Pending
- 2014-11-14 CA CA2928349A patent/CA2928349A1/en not_active Abandoned
- 2014-11-14 WO PCT/EP2014/074554 patent/WO2015071388A1/en not_active Ceased
- 2014-11-14 MX MX2016005855A patent/MX2016005855A/es unknown
- 2014-11-14 HK HK16108771.0A patent/HK1220724A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3068885A1 (en) | 2016-09-21 |
| CN105722980A (zh) | 2016-06-29 |
| HK1220724A1 (zh) | 2017-05-12 |
| KR20160083876A (ko) | 2016-07-12 |
| JP2017501684A (ja) | 2017-01-19 |
| MX2016005855A (es) | 2016-07-13 |
| US20160289677A1 (en) | 2016-10-06 |
| CA2928349A1 (en) | 2015-05-21 |
| WO2015071388A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016122168A (ru) | Антисмысловые конъюгаты, направленные на аполипопротеин b | |
| AU2013306006B2 (en) | Polynucleotides having bioreversible groups | |
| ES2857702T3 (es) | Oligonucleótidos para la reducción de la expresión de PD-L1 | |
| RU2015119411A (ru) | Конъюгаты антисмысловых соединений, направленные на аполипопротеин в | |
| RU2018119315A (ru) | Олигонуклеотиды для индуцирования отцовской экспрессии ube3a | |
| CA2950960A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| UA121117C2 (uk) | Антисенсова нуклеїнова кислота | |
| WO2017004261A1 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
| CA2929651A1 (en) | Polynucleotide constructs having disulfide groups | |
| JP2013510561A5 (ru) | ||
| JP2015532097A5 (ru) | ||
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof | |
| NO334155B1 (no) | Anvendelse av konjugater, for transportering av molekyler via bisykliske membraner og for fremstilling av et medikament og/eller diagnostisk middel samt fremgangsmåte for transport in vitro | |
| IL275902B2 (en) | Antisense oligonucleotides directed against alpha-synuclein and their uses | |
| JP6882735B2 (ja) | 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ | |
| US11479769B2 (en) | Technique for treating cancer using structurally-reinforced S-TuD | |
| CN119487192A (zh) | 小激活核酸分子及其在治疗遗传性血管性水肿中的用途 | |
| Luo et al. | Synthesis of oligonucleotides with glucosamine at the 3′-position and evaluation of their biological activity | |
| CN120379694A (zh) | 跨膜递送系统及其用途 | |
| CN111419867A (zh) | 转运rna分子及其片段用于预防或治疗心脏疾病的用途 | |
| CN107709561A (zh) | 修饰的siRNA及含有该修饰的siRNA的药物组合物 | |
| WO2021035391A1 (zh) | 转运rna分子及其片段用于预防或治疗心脏疾病的用途 | |
| WO2008156172A1 (ja) | 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |